Provided is the use of a combination of (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({ 2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl} methyl)-4-methyl-1,3-oxazolidin-2-one (anacetrapib) and a calcium channel blocker or a fibrate for the prevention or treatment of hypertriglyceridemia or hypertriglyceridemia-associated diseases. A preferred calcium channel blocker is amlodipine. A preferred fibrate is fenofibrate.
